Gross Profit of BioLine RX (BLRX.TA) as of Mar 15, 2026.
BioLine RX Gross Profit
Gross Profit
0USD
Last updated: Mar 15, 2026
Gross Profit of BioLine RX is 2026 0 USD. Gross Profit of BioLine RX was 2025 0 USD. It decreases by % lower compared to the previous year.
The BioLine RX Gross Profit history
3 Years
10 Years
25 Years
Max
GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
6,460 base
Jan 1, 2010
7,738 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
Jan 1, 2019
0 base
| YEAR | GROSS MARGIN (%) |
|---|---|
| 2024 | 67,99 |
| 2023 | 23,08 |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | 77,38 |
| 2009 | 64,60 |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
BioLine RX Revenue
BioLine RX Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
0 USD
-6.86 M USD
-6.31 M USD
Jan 1, 2006
0 USD
-13.06 M USD
-12.93 M USD
Jan 1, 2007
0 USD
-21.8 M USD
-14.48 M USD
Jan 1, 2008
0 USD
-33.31 M USD
-32.08 M USD
Jan 1, 2009
16.3 M USD
-16.14 M USD
-15.69 M USD
Jan 1, 2010
30.33 M USD
3.52 M USD
1.99 M USD
Jan 1, 2011
0 USD
-16.41 M USD
-14.04 M USD
Jan 1, 2012
0 USD
-21.19 M USD
-19.81 M USD
Jan 1, 2013
0 USD
-16.99 M USD
-17.04 M USD
Jan 1, 2014
0 USD
-17.16 M USD
-11.09 M USD
Jan 1, 2015
0 USD
-16.2 M USD
-14.4 M USD
Jan 1, 2016
0 USD
-16.51 M USD
-15.84 M USD
Jan 1, 2017
0 USD
-25.24 M USD
-24.35 M USD
Jan 1, 2018
0 USD
-25.61 M USD
-22.96 M USD
Jan 1, 2019
0 USD
-28.11 M USD
-25.45 M USD
BioLine RX Margins
BioLine RX stock margins
The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.
3 Years
5 Years
10 Years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
67.99 %
0 %
0 %
Jan 1, 2006
67.99 %
0 %
0 %
Jan 1, 2007
67.99 %
0 %
0 %
Jan 1, 2008
67.99 %
0 %
0 %
Jan 1, 2009
64.6 %
-99.02 %
-96.26 %
Jan 1, 2010
77.38 %
11.61 %
6.56 %
Jan 1, 2011
67.99 %
0 %
0 %
Jan 1, 2012
67.99 %
0 %
0 %
Jan 1, 2013
67.99 %
0 %
0 %
Jan 1, 2014
67.99 %
0 %
0 %
Jan 1, 2015
67.99 %
0 %
0 %
Jan 1, 2016
67.99 %
0 %
0 %
Jan 1, 2017
67.99 %
0 %
0 %
Jan 1, 2018
67.99 %
0 %
0 %
Jan 1, 2019
67.99 %
0 %
0 %
BioLine RX Stock analysis
What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.com.
Frequently Asked Questions about BioLine RX stock
On Eulerpool you can find the complete historical development of Gross Profit BioLine RX since 2006 – with annual values, charts, and detailed analysis.
Income Statement — BioLine RX
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
All Key Metrics — BioLine RX
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth